Patients should focus on nutrient-dense foods that support muscle function, digestion, energy levels, and long-term weight maintenance
Similarly, immunogenic potential is an ever-present concern in macromolecular medicinal chemistry and dual agonists capable of simultaneously binding at more than one cellular site increase the risk of an immune response [12]
Treatment decisions depend on provider evaluation, safety considerations, and individual goals
The short treatment duration becomes a feature rather than a limitation when the weight loss goal is modest
This stance, while aimed at ensuring patient safety, inadvertently raises a critical issue
The drug was first approved for that purpose in 2017 and was then approved as a type 2 diabetes pill called Rybelsus and, most recently, as an injection to treat obesity called Wegovy